WuXi Vaccines Achieves Weather-Tight Construction Milestone on Main Building of Manufacturing Facility Despite COVID-19
SHANGHAI and DUNDALK, Ireland, March 16, 2021 /PRNewswire/ WuXi Vaccines, a world-leading vaccine Contract Development and Manufacturing Organization (CDMO), today announced it achieved the weather-tight construction milestone of its vaccine manufacturing facility currently under construction in Dundalk, Ireland, while the company demonstrated extraordinary resilience despite COVID-19 challenges. The facility is expected to be operational in 2022. The modular lab was already in GMP operations since July 2020.
WuXi Vaccines signed a 20-year vaccine manufacturing contract valued at approximately USD $3 billion with a global pharmaceutical company in February 2020, following the signing of the letter of intent in May 2019. To implement this landmark agreement, WuXi Vaccines invested USD $240 million to build its vaccine manufacturing facility in Dundalk, Ireland. T